We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.

Delisted

ITCI was delisted on the 1st of April, 2025.

149 hedge funds and large institutions have $1.25B invested in Intra-Cellular Therapies Inc. in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 60 increasing their positions, 32 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more call options, than puts

Call options by funds: $91M | Put options by funds: $41.1M

88% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 32

66% more capital invested

Capital invested by funds: $755M → $1.25B (+$497M)

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

50% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 22

7% more funds holding

Funds holding: 139149 (+10)

Holders
149
Holders Change
+10
Holders Change %
+7.19%
% of All Funds
3.06%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.06%
New
33
Increased
60
Reduced
32
Closed
22
Calls
$91M
Puts
$41.1M
Net Calls
+$49.8M
Net Calls Change
+$46.6M
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$2.26M +$356K +17,600 +25%
State of New Jersey Common Pension Fund D
52
State of New Jersey Common Pension Fund D
New Jersey
$2.15M +$1.7M +83,840 New
California State Teachers Retirement System (CalSTRS)
53
California State Teachers Retirement System (CalSTRS)
California
$2.13M +$57.4K +2,834 +4%
Group One Trading
54
Group One Trading
Illinois
$1.86M +$1.46M +72,353 New
Federated Hermes
55
Federated Hermes
Pennsylvania
$1.75M +$504K +24,906 +57%
Bank of America
56
Bank of America
North Carolina
$1.73M -$542K -26,792 -28%
Ohio Public Employees Retirement System (OPERS)
57
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.65M
AQR Capital Management
58
AQR Capital Management
Connecticut
$1.59M +$12.5K +616 +1%
CS
59
Credit Suisse
Switzerland
$1.57M -$1.72M -84,934 -58%
Wells Fargo
60
Wells Fargo
California
$1.37M +$466K +23,031 +76%
CM
61
Caption Management
Oklahoma
$1.36M +$1.07M +53,050 New
New York State Common Retirement Fund
62
New York State Common Retirement Fund
New York
$1.32M +$211K +10,400 +25%
Simplex Trading
63
Simplex Trading
Illinois
$1.25M +$199K +9,809 +25%
FSA
64
Franklin Street Advisors
North Carolina
$1.22M
UBS AM
65
UBS AM
Illinois
$1.2M +$911 +45 +0.1%
Legal & General Group
66
Legal & General Group
United Kingdom
$1.07M +$316K +15,592 +59%
PAI
67
Palo Alto Investors
California
$960K
SM
68
SG3 Management
Puerto Rico
$898K +$709K +35,000 New
Citigroup
69
Citigroup
New York
$889K +$162K +8,016 +30%
Stifel Financial
70
Stifel Financial
Missouri
$877K +$358K +17,690 +107%
AIG
71
American International Group
New York
$863K +$49.4K +2,441 +8%
MML Investors Services
72
MML Investors Services
Massachusetts
$801K +$632K +31,200 New
SG Americas Securities
73
SG Americas Securities
New York
$800K +$202K +9,956 +47%
Manulife (Manufacturers Life Insurance)
74
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$797K +$5.79K +286 +0.9%
William Blair & Company
75
William Blair & Company
Illinois
$791K +$624K +30,820 New

ITCI Hedge Fund Activity: Q2 2020 in Review

149 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2020, worth a combined $1.25B — up 66% from $755M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ITCI positions and 22 closed out — a net gain of 11 holders — while 60 added to existing stakes and 32 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $15.9M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $25.4M sold.

  • 149 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2020, up from 139 in Q1 2020.
  • Funds reported $1.25B of Intra-Cellular Therapies Inc. stock for Q2 2020, up 66% quarter-over-quarter.
  • 33 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2020 and 22 closed out, a net change of +11 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2020 was Fidelity Investments, an estimated $15.9M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2020 was Consonance Capital Management, an estimated $25.4M sold.

Based on aggregated 13F filings for Q2 2020.